ZD7114, [( S )-4-[2-(2-hydroxy-3 phenoxypropylamine)ethoxy]-N-(2-methoxyethyl) phenoxyacetamide], and ZD2079, [(R)-N-(2-[4-(carboxymethyl)phenoxy]ethyl)-N -(&beta;-hydroxyphenethyl)ammonium chloride], are &beta;3-adrenoceptor stimulants with selectivity for brown adipose tissue. ZD7144 is the hydrochloride salt of the S-enantiomer of the racemic amide ZD2079. They were developed as potential novel treatments for obesity and non-insulin-dependent diabetes mellitus. Male and female rats were dosed separately by gavage for a minimum of 28 days with 0, 10, 50, and 500 mg/kg/day of ZD7114 or with 0, 10, 30, and 150 mg/kg/day of ZD2079. Two further groups of male and female rats were dosed with 0 and 500 mg/kg/day of ZD7114 for 28 days and were then allowed a 6-wk, undosed withdrawal period. At high doses, both compounds caused urinary tract toxicity, which primarily affected the distal tubules and collecting ducts of the kidney via tubular necrosis. They also caused ureteric inflammation, cystitis, and accumulation of crystalline inclusions throughout the urinary tract. As a result of urinary tract toxicity, affected animals from one or both studies showed reduced red blood cell indices, lower platelet counts, and higher white cell counts. Blood chemistry revealed lower plasma concentrations of glucose (7.28 &plusmn; 1.37 compared to 8.11 &plusmn; 0.65 for the control) and total protein (63.42 &plusmn; 3.65 compared to 69.17 &plusmn; 3.24 for the control) and increased plasma urea (37.15 &plusmn; 19.96 compared to 8.09 &plusmn; 0.87 for the control). Urinalysis showed an increase in the number of crystals, blood, and protein. In the urinary tract, the severe crystalluria with accumulation of crystalline material indicated that this may have a role in the etiology of the target organ toxicity. Poor solubility of the compounds at normal urinary pH was considered a possible mechanism for the crystalluria.
INTRODUCTION
Brown adipose tissue (BAT) is recognized as a major source of thermogenesis in many mammals and as the effector of nonshivering thermogenesis (NST) . BAT is thought to be under sympathetic nervous system control and is thought to be mediated by an atypical&dquo; f33&dquo; adrenoceptor, which, upon stimulation, causes mobilization and oxidation of fat and an increase in metabolic rate (8) .
ZD7114, [(S)-4-[2-(2-hydroxy-3 phenoxypropylamine)ethoxy]-N-(2-methoxyethyl) phenoxyacetamide], and ZD2079, [(R)-N-(2-[4-(carboxymethyl)phenoxy]ethyl)-A~-((3-hydroxyphenethyl)ammonium chloride], are (33-adrenoceptor stimulants with selectivity for BAT ( Fig. 1 ). By stimulating BAT, these novel agents increase whole body oxygen consumption in conscious rats, cats, and dogs. They were developed for use in treating obesity and non-insulin-dependent diabetes mellitus (5) . Both compounds were examined in 1-mo rat oral toxicity studies as part of their preclinical safety evaluation. In these studies, the urinary tract was identified as the target for toxicity. A water-loading study was also performed to investigate the effect of urine concentration on the induction of the changes. METHODS Both ZD7144 and ZD2079 were formulated as a suspension in 0.5% w/v hydroxypropyl methylcellulose (HPMC) (Methocel Dow Chemical Europe) in 0.1 % w/ v aqueous polysorbate 80 (PS 80, Fisher Scientific, UK) via agitation using a Silverson high-speed high-shear mixer (Silverson Machines Ltd., Chesham, UK). The concentration was calculated to give constant dose volume of 0.5 ml per 100 g body weight for each dose level. Male and female APf,SD Wistar-derived, Alderley Park rats (Alpk) were dosed separately by gavage for a minimum of 28 days with 0, 10, 50, and 500 mg/kg/day of ZD7114 (12/sex/group) or with 0, 10, 30, and 150 mg/ kg/day of ZD2079 ( 10/sex/group). Two further groups of male and female rats (12/sex/group) were dosed with 0 and 500 mg/kg/day of ZD7114 for 28 days and were then allowed a 6-wk, undosed withdrawal period. The body weight and food/water intake of animals was recorded; blood samples were taken for measurement of hematology and blood chemistry indices. Urine samples were collected, and the volume and specific gravity of each sample were measured and the urine color and appearance were noted. Samples were tested semiquantitatively for glucose, protein, ketones, bilirubin, blood, and pH by a test-strip method (Bayer plc, Diagnostics Division, Newbury, UK), and a centrifuged deposit of each sample was examined microscopically for blood cells, leukocytes, epithelial cell casts, and crystals.
Animals were euthanatized at the end of the study and were given a full macroscopic examination. The kidneys and urinary bladder were examined visually for size, color, and any macroscopic abnormalities. The kidneys were weighed, and selected tissues were processed using standard histological techniques and were embedded in par- affin wax. Sections were cut and stained with hematoxylin and eosin for microscopic examination. Additionally, samples of kidney and urinary bladder were recovered from buffered formalin, and sections were cut on a freezing microtome. These were examined under polarized light with a light microscope for the presence of crystalline material.
In order to determine the effect of urine flow/concentration (by providing excess of water by oral gavage) on the induction of crystalluria and renal toxicity, 3 groups of female rats (5/group) were fasted overnight and dosed the following day with 2,000 mg/kg of ZD2079 (as an HPMC/PS80 suspension at 10 ml/kg), either with or without subsequent water loading, and a control group received the vehicle and was water loaded. The dose was determined based on a previous single-dose (2, 000 mg/ kg) acute study; this dose had been shown to cause renal damage in rats. One hour before dosing with either the control or 2,000 mg/kg ZD2079 formulation, animals received a 2%-body weight water load by gavage, with similar water loading at approximately 2, 4, and 6 hr postdosing. The body weights and water intakes of all animals were recorded, urine samples were collected, and the following parameters were measured at 2, 4, 6, and 24 hr: pH, specific gravity, quantitative protein and glucose, and N-acetyl-(3-glucosaminidase, alkaline phosphatase, and q-glutamyl transpeptidase activities. All animals were subjected to a necropsy examination approximately 48 hr after dosing. Kidneys, ureters, and bladders from these animals were taken for routine histological examination.
Numerical data were analyzed (using the SAS computer system) by analysis of variance (ANOVA); we allowed for the effects of group, sex, and replicate system. Each dose group mean was compared to that of the control group using a Student's t-test, in which the standard error was derived from the residual mean square in the ANOVA. The study conduct and procedures were carried out in accordance with ZENECA policy and quality assurance procedures for Good Laboratory Practice.
RESULTS
The major finding in these studies was urinary tract toxicity in high dose-group animals; this toxicity resulted in morbidity and mortality. This was particularly evident in females given 500 mg/kg/day of ZD7114; of these animals, 63% percent were euthanatized prematurely for humane reasons. There were no toxic effects in other organ systems. Clinical observations included subdued behavior, hunched posture, piloerection, loss of skin tone, labored respiration, urine staining of the coat, and excess salivation. Mortality was low in animals dosed with ZD2079 and was confined to 1 high-dose female that had been given 150 mg/kg/day of ZD2079.
Hematological measurements for female rats given ZD7114 and ZD2079 are shown in Tables I and II, re- spectively. At the end of the dosing period, females dosed at 500 mg/kg/day of ZD7114 showed lower values for red blood cell indices (hemoglobin concentration, red blood cell count, and hematocrit), mean cell volume, mean cell hemoglobin, and platelet counts than did control animals. They also showed higher white blood cell counts, principally associated with an increase in neutrophils. There were no significant hematological changes in the females given ZD2079, with the exception of top dose group females, which showed higher white blood cell counts, principally due to an increase in neutrophils and lymphocytes. Blood chemistry results for females given ZD7114 and ZD2079 are shown in Tables III and  IV . At the end of dosing period, top dose females given ZD7114 showed slightly lower plasma concentrations of glucose and total protein. An increased plasma urea concentration was seen for all 3 ZD7114 dose groups and for ZD2079 high dose-group females. At the end of the dosing period, there was an increase in the volume of urine for the males (24.50 ml/16 hr) and females (19.00 ml/16 hr) given 500 mg/kg/day of ZD7114 compared with controls (male, 16.25 ml/16 hr; female, 11 .00 ml/16 hr) and for females given 150 mg/ kg/day of ZD2079 (18.00 ml/16 hr) compared with con-TABLE I.-Selected hematological measurements in female rats given ZD7114 (day 25).&dquo; a Group 1. n = 12, dose = 0 gikg/day-, group 11, n = 12, dose = 10 mg/kg/day; group 111, n = 11, dose = 50 mg/kg/day; group IV, n = 6, dose = 500 mg/kg/day. Group I, n = 10, dose 0 = mg/kg/day; group II, n = 10, dose = 10 mg/kg/day; group III, n = 10, dose = 30 mg/kg/day; group IV, n = 9, dose = 150 mg/kglday. b Mean ± SD.
* p < 0.05. ** p < 0.01. *** p < 0.001. trols (10.00 ml/16 hr). Microscopic and reagent strip examination of urine from some high-dose females given ZD7144 and ZD2079 showed + + or + + + grades of red blood cells, protein, blood, and leukocytes. In controls, these parameters normally have a + or 0 grading. An increase in the number of crystals in the urine was seen in some males and females dosed at 500 mg/kg/day and in some females dosed at 50 mg/kg/day of ZD7114. No crystals were seen in urinalyses for the females given ZD2079. Microscopically, crystals from the urine were either needle shaped or cylindrical with blunt ends. By the end of the withdrawal period, hematological, blood chemistry, and urinalysis indices affected during the dosing phase of the study had generally returned to control levels. However, the few surviving females previously given 500 mg/kg/day of ZD7114 still showed slightly lower red blood cell values; hemoglobin was 15.0 ± 0.47 compared with 15.82 ~-0.62 for the control (statistical significance: p < 0.001), and hematocrit was 0.40 ± 0.01 compared with the control value of 0.42 ± 0.02 (statistical significance: p < 0.01), with evidence of proteinuria and hematuria. There was also a minor increase in the white cell count, which was principally associated with an increase in lymphocytes.
Macroscopic abnormalities were seen in the kidneys and urinary bladders of animals given 500 mg/kg/day of ZD7114 and 150 mg/kg/day of ZD2079. The kidney changes (cream/brown discoloration and enlargement) were seen in 3 of 12 males and in 9 of 12 females given ZD7114 and in all females (10/10) dosed with ZD2079.
Bladder changes were only observed in 7 of 12 females given ZD7114, and these included luminal distension, red discoloration, and thickening of the bladder wall.
The mean kidney weight (relative to body weights) at the end of the dosing period for males dosed at 500 mg/ kg/day of ZD7114 was 1.03 -!-0.35, compared with 0.82 ± 0.07 for the control group. At the end of the with-drawal period, there was an increase to 0.97 ± 0.03 for high-dose female mean kidney weight, compared with 0.78 ± 0.07 for the control group. Also, the mean relative kidney weight for high-dose females given ZD2079 was 1.35 ± 0.14, compared with 0.90 ± 0.06 for the control. The mean kidney weights for animals in the low-and mid-dose groups were not affected.
Histologically, marked nephropathy, with changes targeting the distal convoluted tubules, loop of Henle, and collecting ducts, was seen in females given 500 mg/kg/ day ZD7114 and 150 mg/kg/day ZD2079. Affected kidneys showed tubular damage with tubular necrosis, tubular atrophy, tubular basophilia, tubular dilatation (Fig.  2 ), interstitial inflammation, and papillary collecting duct and pelvic epithelial hyperplasia (Fig. 3 ). In addition to the cellular debris noted within tubules (particularly in the papilla), eosinophilic inclusions of a feathery or crystalline nature were seen, commonly in association with an acute inflammatory-cell exudate. Birefringent crystalline inclusions were seen under polarized light on examination of fixed frozen sections of kidneys and urinary bladders in a number of females dosed with 500 mg/kg/ day of ZD7114. Microcrystals were identical to those seen in the urine samples (cylindrical with blunt ends or needle shaped), and they were mainly confined to the lumen of the renal pelvis and urinary bladder (Fig. 4 ). Although they were seen following hematoxylin and eosin staining of standard wax-processed tissues, no crystalline inclusions were apparent under polarized light on examination of fixed frozen sections of a number of kidneys from females dosed with 150 mg/kg/day ZD2079.
Some of the deceased animals that had been given ZD7114 showed acute hemorrhagic cystitis (5/12; Fig. 5 ), ulceration of bladder mucosa (1/12; Fig. 6 ), and acute ureteric inflammation (2/12). One female given ZD2079 also showed ulceration of the renal pelvis and ureter. These changes were considered responsible for the early deaths of these animals. Subacute/chronic pyelitis, ureteritis, and cystitis accompanied by regenerative hyperplastic changes of the urothelium of the renal pelvis, ureter, and bladder were also a feature in some animals.
These changes were usually associated with hemorrhage and mixed inflammatory-cell infiltration. At the end of withdrawal period (ZD7114 only), surviving females given 500 mg/kg/day showed changes of a chronic nature. These included interstitial inflammation ( Fig. 7) , papillitis, pyelitis, tubular regeneration, collecting duct epithelial hyperplasia ( Fig. 8 ), chronic cystitis, and hyperplasia of the transitional epithelium lining the renal pelvis and the ureter (Fig. 9 ). These changes were accompanied by chronic inflammatory cell exudate (mainly lymphocytes and plasma cells) and fibrosis. Mitotic figures were frequently seen in the epithelial lining of the collecting ducts, and there was evidence of karyomegaly.
In the investigatory study, all rats given a single dose of 2,000 mg/kg of ZD2079 (with or without water loading) that were examined after 48 hr displayed changes in the kidneys that were essentially similar to those described above following dosing for 28 days with ZD7114 and ZD2079 at 500 and 150 mg/kg/day, respectively. In addition, ureteral epithelial ulceration with inflammation and hyperplasia was seen in 1 animal dosed with ZD2079 alone and in 2 animals dosed with ZD2079 and water loaded. This was associated with feathery crystalline inclusions within the ureteral lumen of the animal dosed with ZD2079 alone. No changes were seen in the urinary bladder, and there were no clear changes in urinary enzyme activity. 
DISCUSSION
Administration of daily doses of 500 mg/kg of ZD7114 or 150 mg/kg/day of ZD2079 in rats for a month resulted in necrotic and inflammatory urinary tract lesions that affected kidneys (distal tubules, loop of Henle, and the collecting ducts), urinary bladders, and associated structures. Both compounds caused lesions of similar intensity, and they predominantly affected high-dose females. This organ toxicity led to morbidity and mortality in some female rats. Although increases in urinary enzymes were not readily apparent, changes in blood chemistry, hematological parameters, and urinalysis in high-dose females were considered a consequence of this kidney and urinary bladder damage. An excess quantity of crystal deposition was seen in the urinary tracts of some highdose females given ZD7114 and ZD2079.
Chemicals or their metabolites may crystallize in the tubular lumen as they are concentrated in the loop of Henle and the distal nephron. Several therapeutic agents, such as sulphonamides (10) , quinolone antibiotics (1, 7), purine analogues (10, 11) , and adenine (3), are known to produce crystalluria, crystal deposition, and obstructive nephropathy when high doses are given in laboratory animals. Microcrystalluria (and frequently hematuria) has occurred following ciprofloxacin administration in animals and is dependent on the pH of the urine (7) . In these studies, the excess quantity of crystals in the urine and the deposition of crystals throughout the urinary tract in some rats may indicate that crystalluria has a role in the etiology of the target organ toxicity. pH may affect the degree of ionization and solubility of organic acids and bases and may lead to crystallization (4). For both compounds, pH profile data indicate that solubility is pH dependent, the compounds being most soluble at acidic pH values (2, 9) . In the investigatory study, there was no evidence that ZD2079 administration had an effect on urinary pH. However, at pH 6-7 (normal FIG. 7. -Kidney of drug withdrawal rat, showing chronic interstitial nephritis (asterisks); rat had been given 500 mg/kg/day of ZD7114 for 28 days and was then allowed a 6-wk undosed period. H&E.
X63.
FIG. 8.-Kidney of drug withdrawal rat, showing chronic papillitis (asterisks), pyelitis, tubular regeneration, and collecting duct epithelial hyperplasia (arrows); rat had been given 500 mg/kg/day of ZD7114 for 28 days and was then allowed a 6-wk undosed period. H&E; X63. urine pH), ZD2079 is at its least soluble (6) , and the compound may therefore come out of solution. Attempts to reduce crystallization of ZD2079 by diluting the urine following water loading were unsuccessful.
